Business
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase 2b trial within UNITE4TB, following completion of a Phase 2a in adults with drug-susceptible pulmonary TB (DS-TB) in combination with RZE.1In the new Phase 2b trial in adults with DS-TB, AlpE will be dosed for two months together with RZE, patients then continue only with RH2 for
About this update from Bioversys Ag
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) --","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase 2b trial within UNITE4TB, following completion of a Phase 2a in adults with drug-susceptible pulmonary TB (DS-TB) in combination with RZE.1","length":266,"tagName":"p"}]},{"val":[{"type":"text","content":"In the new Phase 2b trial in adults with DS-TB, AlpE will be dosed for two months together with RZE, patients then continue only with RH2 for 18 weeks.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b results are expected by the end of 2027.","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"In addition, BioVersys plans to initiate a Phase 2 trial in TB meningitis in H1 2026.","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":551,"olType":false},{"type":"text","content":"BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, that the first patient has been dosed in a pulmonary TB Phase 2b clinical trial, evaluating the efficacy, safety and pharmacokinetics of alpibectir-ethionamide (AlpE) in combination with first-line TB drugs (NCT05807399).","length":476,"tagName":"p"},{"type":"text","content":"In this new Phase 2b trial, a portion of the recruited adults with drug sensitive pulmonary tuberculosis (DS-TB) will be dosed for 2-months with RZE in combination with AlpE, followed by 18 weeks with RH alone, to assess e...